NASDAQ:CYTR

CytRx - CYTR Stock Forecast, Price & News

$0.10

+0.01 (+11.70%)

(As of 09/30/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.09
▼
$0.10
50-Day Range: $0.08
▼
$0.13
52-Week Range: $0.05
▼
$0.86

Volume: 56,090 shs
Average Volume: 48,810 shs
Market Capitalization: $4.30 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

About CytRx (NASDAQ:CYTR) Stock

CytRx Corporation, a biopharmaceutical research and development company, focuses on oncology and rare diseases. It engages in the discovery, research, and clinical development of novel anti-cancer drug candidates that employ novel linker technologies to enhance the accumulation and release of cytotoxic anti-cancer agents at the tumor. The company's lead candidates include linker activated drug release (LADR) -7, LADR-8, LADR-9, and LADR-10; and Aldoxorubicin, a conjugate of prescribed cytotoxin agent doxorubicin that binds to circulating albumin in the bloodstream and to concentrate the drug at the site of the tumor. It also provides ACDx, an albumin companion diagnostic product to identify patients with cancer who are most likely to benefit from treatment with these drug candidates. CytRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Stock News Headlines

September 28, 2022 | americanbankingnews.com

CytRx (NASDAQ:CYTR) Research Coverage Started at StockNews.com

September 23, 2022 | finance.yahoo.com

CytRx Corporation Relaunches as LadRx Corporation

September 8, 2022 | seekingalpha.com

European patent office awards CytRx patent for LADR platform

September 7, 2022 | finance.yahoo.com

European Patent Office Awards CytRx Key Patent

August 3, 2022 | marketwatch.com

Temperature Data logger Market Size: Market Growth at a CAGR of 3.64% to Outstrip USD 1364.75 Million by 2028

August 2, 2022 | thestreet.com

Whiplash: S&P Veers to All-Time High Before Crashing

May 19, 2022 | finance.yahoo.com

CytRx Announces Distribution of Series D Preferred Stock to Holders of Its Common Stock

May 18, 2022 | marketwatch.com

Kinase Inhibitors Market Report [2022]- Historical, Current, and Projected Size, in terms of value

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CYTR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CytRx and its competitors with MarketBeat's FREE daily newsletter.

CYTR Company Calendar

Last Earnings: 8/11/2022
Today: 10/01/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CYTR
CUSIP: N/A
CIK: 799698
Web: www.cytrx.com
Phone: (310) 826-5648
Fax: 310-826-6139
Employees: 3
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-13,180,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -396.93%
Return on Assets: -137.17%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.83
Quick Ratio: 1.83

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.02 per share
Price / Book: 4.78

Miscellaneous

Outstanding Shares: 45,040,000
Free Float: 39,912,000
Market Cap: $4.30 million
Optionable: Not Optionable
Beta: 2.10

Key Executives

Mr. John Y. Caloz (Age 70)
CFO, Treasurer & Sr. VP
Comp: $500k

Dr. Stephen Snowdy Ph.D. (Age 52)
Chief Exec. Officer

Molly Carey Poarch
Global & U.S. Head of Corp. Communications

Ms. Molly Painter (Age 46)
Pres of USA and Head of Launch & Commercial Operations

Terri Stevens
Chief Bus. Officer

Ms. Cristina Newman
Corp. Sec.

Dr. Felix Kratz Ph.D. (Age 59)
Sr. VP, Drug Devel.

Key Competitors

View All Competitors

CYTR Stock - Frequently Asked Questions

How have CYTR shares performed in 2022?: CytRx's stock was trading at $0.49 on January 1st, 2022. Since then, CYTR shares have decreased by 80.5% and is now trading at $0.0955.
View the best growth stocks for 2022 here.
How were CytRx's earnings last quarter?: CytRx Co. (NASDAQ:CYTR) posted its quarterly earnings results on Thursday, August, 11th. The company reported ($0.02) earnings per share (EPS) for the quarter.

What is CytRx's stock symbol?: CytRx trades on the NASDAQ under the ticker symbol "CYTR."
How do I buy shares of CytRx?: Shares of CYTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is CytRx's stock price today?: One share of CYTR stock can currently be purchased for approximately $0.10.
How much money does CytRx make?: CytRx (NASDAQ:CYTR) has a market capitalization of $4.30 million.
How can I contact CytRx?: CytRx's mailing address is 11726 San Vicente Blvd Ste 650, Los Angeles, California 90049-5079. The official website for the company is www.cytrx.com. The company can be reached via phone at (310) 826-5648, via email at info@cytrx.com, or via fax at 310-826-6139.

This page (NASDAQ:CYTR) was last updated on 10/1/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms